Gross Margin % is calculated as gross profit divided by its revenue. Bio-Techne's Gross Profit for the
three
months ended in Sep. 2024 was $183 Mil. Bio-Techne's Revenue for the
three
months ended in Sep. 2024 was $289 Mil. Therefore, Bio-Techne's Gross Margin % for the quarter that ended in Sep. 2024 was 63.23%.
The historical rank and industry rank for Bio-Techne's Gross Margin % or its related term are showing as below:
TECH'
s Gross Margin % Range Over the Past 10 Years
Min: 65.41 Med: 67.34 Max: 68.42
Current: 65.51
During the past 13 years, the highestGross Margin % of Bio-Techne was 68.42%. The lowest was 65.41%. And the median was 67.34%.
TECH's Gross Margin % is ranked better than 56.63% of 747
companies
in the Biotechnology industry
Industry Median: 60.58
vs TECH: 65.51
Bio-Techne had a gross margin of 63.23% for the quarter that ended in Sep. 2024 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Bio-Techne was 0.30% per year.
Bio-Techne Gross Margin % Historical Data
The historical data trend for Bio-Techne's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bio-Techne's Gross Margin %
For the Biotechnology subindustry, Bio-Techne's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio-Techne (NAS:TECH) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio-Techne had a gross margin of 63.23% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bio-Techne Gross Margin % Related Terms
Thank you for viewing the detailed overview of Bio-Techne's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 